The current site selection model is flawed: a site’s true potential is stifled when the wrong trials come their way. With a huge portion of trials going to large academic research centers, the remaining majority of sites with experienced, motivated teams feel obligated to accept nearly every opportunity they receive – even the ones that aren’t a match for their team and patients.